[Effectiveness and adverse effects of XXXX in @entity323 ].

@entity1 @entity1671 @entity7856 @entity323 @entity227 @entity7855 @entity10 @entity121
@entity7855 is a selective and by oral administration potent type-5 phosphodiesterase ( @entity7856 ) inhibitor, which increases the erection by corpus cavernosum smooth @entity121 . In a non-placebo controlled study, 134 @entity1 with @entity323 were treated with oral @entity7855 . The aim of the study was to estimate the efficacy and adverse effects of this treatment. 51 @entity1 (38%) had psychogenic, and 83 (62%) organic origin of the @entity323 . 73 of them have already had some treatment for this problem before. The effective dose was 50 mg for 84 @entity1 (63%), 100 mg for 32 (24%) and 25 mg for 4 @entity1 . The treatment was effective for 120 @entity1 (90%). The most common adverse effect was @entity1671 in 18 (13%) and @entity10 in 9 (7%) cases, two @entity1 had @entity10 and @entity1671 together. Nasal congestion and @entity227 were complained by two @entity1 . Two @entity1 reported prolonged (max. 2h) erections. Cardiological investigation was performed for cardiovascular @entity1 and for @entity1 with risk factors. Exact criteria of the cardiological opinion of @entity7855 treatment are reviewed. Cardial or other serious adverse effects were not observed. It was not necessary to stop the treatment because of the adverse effects. The authors found, that @entity7855 is an effective and safe treatment for the @entity323 .
